VIJOINT HCC

VIJOINT HCC
Product Description

Vijoint HCC is a patented fixed combination of Hyaluronic Acid (HA) sodium salt 2%, chondroitin-Sulfate 2% (CS) and Hydroxypropyl beta-Cyclodextrin 1%.
HA AND CS ACT IN SYNERGY TO CONTRAST DISEASE SYMPTOMS AND SLOW DOWN ITS PROGRESSION.

YOUNG TARGETHYALURONIC ACID SYSADOA: SYMPTOMATICSLOW-ACTING DRUG: improving pain, inflammation and joint function.

ELDER TARGET
CHONDROITINSULFATE DMOAD. DISEASE MODIFYING OSTEOARTHRITIS DRUG:

  • Favouring subchondral bone formation
  • Reducing the rate of decline in minimum joint space
Vijoint HCC, as recommended by international Guidelines, contains “pharma grade” CS of marine origin (from shark) that differs for anticoagulant, anti-inflammatory and stimulating neurite outgrowth activities, from common terrestrial sources.
Vijoint HCC is a 3D complex, formulated as HA functionalized with beta-cyclodextrin, a molecular “basket”, which hosts inside the chondroitin-sulphate and:
  • overcomes the poor absorption (only 12-13%) of chondroitin taken orally
  • increases the viscosity of hyaluronic acid and its loading in the joint
  • protects hyaluronic acid from the enzymatic degradation of hyaluronidases
IMPROVED RESISTANCE TO THE HYALURONIDASES

Hyaluronic acid is subject to progressive degradation when in contact with hyaluronidases enzymes. Vijoint HCC, as a polymeric complex of hyaluronic acid, chondroitinsulphate and cyclodextrin, has a significantly lower enzymatic degradation rate than preparations based on hyaluronic acid only. An “in vitro” study showes the VIJOINT HCC better resistance to the hyaluronidases, expressed by a reduced formation of N-acetylexosamines terminals exposed by enzymatic “cutting action". Vijoint HCC exhibits a relevant reduction in enzymatic degradation compared to the combination of hyaluronic acid and chondroitin sulfate and not only to the solution containing sodium hyaluronate alone.

Biofarma S.p.A.

  • IT
  • 2015
    On CPHI since
  • 5
    Certificates
  • 500 - 999
    Employees
Company types
Manufacturer/Innovator
Specifications

Biofarma S.p.A.

  • IT
  • 2015
    On CPHI since
  • 5
    Certificates
  • 500 - 999
    Employees
Company types
Manufacturer/Innovator

More Products from Biofarma S.p.A. (4)

  • Lenoid

    Product Lenoid

    Hemorrhoidal disease (HD) is one of the most common anorectal benign disorder affecting millions of people around the world. Almost 75% of all adults develop piles at some point in their life. Lenoid™ cream is a medical device indicated for the treatment of hemorrhoidal disease (internal and external hemor...
  • Respecta Balance Gel

    Product Respecta Balance Gel

    Respecta® Balance Gel is a medical device specifically studied for rebalancing the physiological pH and vaginal microbiota that represents an effective adjuvant for the treatment of vaginitis and vaginosis.

    Thanks to the synergistic action of its components:
    • Restores physiological vagina...
  • Gastro Stop

    Product Gastro Stop

    GASTRO STOP is a class IIa medical device, having an anti-reflux action and containing sodium alginate, sodium bicarbonate, sodium carbonateand calcium carbonate.

    PRODUCT

    The product is indicated to reduce gastro-oesophageal reflux diseasesymptoms, including heartburn, gastric pyrosis during ...
  • VIJOINT - VISCOSUPPLEMENTATION

    Product VIJOINT - VISCOSUPPLEMENTATION

    Vijoint, provides a linear intermediate (~1,000-1,500 KDa) Molecular Weight Hyaluronic Acid (HA) for intra-articular viscosupplementation. A recent review highlights that: • HA preparations with Molecular weight (MW) between 500 and 1,500 KDa can achieve maximum concentration in the joint • th...

Biofarma S.p.A. resources (2)

  • Brochure Biofarma Group Presentation

    The CDMO that grows by innovatingBiofarma Group is the new Italian and European market leader in the development, manufacture and packaging of supplements, medical devices, probiotic-based drugs and cosmetics, exclusively for third parties.

  • Video Biofarma Group - Multilayer Technology

    Technology for the oral administration – in a single product – of formulations with active substances or mixtures of active ingredients for diversified sustained and controlled release, for a more efficacious action in the body.